F-1/A: Charming Medical Limited Files for Nasdaq IPO, Reports Strong Revenue and Net Income Growth Amidst Expansion Plans

Charming Medical Limited, a Hong Kong-based provider of TCM-inspired beauty and wellness services, has filed for an initial public offering on the Nasdaq Capital Market, reporting significant revenue and net income growth for fiscal year 2025 while outlining strategic expansion and diversification plans.

Summary

• Charming Medical Limited, operating under the Beauty Lab Group brand, provides Traditional Chinese Medicine (TCM)-inspired beauty, wellness, and postpartum services and products through four wellness centers in Hong Kong.
• The company reported total revenues of US$6,221,751 for the fiscal year ended March 31, 2025, a 3.4% increase from US$6,015,375 in fiscal year 2024.
• Net income significantly increased by 45.9%, reaching US$1,199,085 in FY2025 compared to US$821,743 in FY2024.
• Revenue from beauty, wellness, and postpartum services constituted 96.0% of total revenue in FY2025 (US$5,967,277), driven by an 11.2% increase in average customer spending despite a 5.2% decrease in customer numbers.
• Sales of products saw a substantial increase of 133.5%, from US$88,992 in FY2024 to US$207,766 in FY2025, attributed to new customer subscriptions and sales to franchisees.
• The company launched a franchise model in March 2025, generating US$46,708 in revenue from pre-opening services for its first franchisee, with a total of three franchisees as of the filing date.
• Consultancy services revenue decreased from US$112,569 in FY2024 to nil in FY2025, as demand for these services declined with economic improvement post-COVID-19.
• Operating expenses decreased by 3.5% to US$4,832,813 in FY2025, primarily due to a US$136,975 reduction in rental expenses from closing a store in Central, Hong Kong, and a US$128,250 decrease in depreciation as leasehold improvements became fully depreciated.
• The company's working capital deficit improved from US$2,212,261 in FY2024 to US$1,581,254 in FY2025.
• As of March 31, 2025, cash and cash equivalents stood at US$816,771, supplemented by US$1,441,099 in certificates of deposit and US$503,453 in US Treasury Bills, providing liquidity for the next 12 months.
• The company is offering 1,600,000 Class A Ordinary Shares at an anticipated price between US$4.00 and US$6.00 per share, aiming to raise approximately US$6.6 million in net proceeds.
• Proceeds from the IPO are earmarked for expanding business and geographic coverage (40%), potential strategic investments and acquisitions (30%), research and development (10%), and general working capital (20%).

Sentiment

Score: 7

Explanation: The company demonstrates strong financial growth with increased revenue and net income, an improving working capital position, and clear strategic plans for expansion and diversification, including a new franchise model. However, the auditor's going concern opinion, significant regulatory uncertainties related to Hong Kong and PRC laws, intense competition, and the inherent risks of an unproven franchise model introduce notable caution. The dual-class share structure also concentrates control, which could be a concern for minority investors. The overall sentiment is positive due to growth and strategic direction, but tempered by substantial operational and regulatory risks.

Positives

• Total revenues increased by 3.4% to US$6,221,751 in FY2025, demonstrating continued business growth.
• Net income grew significantly by 45.9% to US$1,199,085 in FY2025, indicating improved profitability.
• The working capital deficit improved from US$2,212,261 in FY2024 to US$1,581,254 in FY2025, reflecting better financial management.
• The launch of a new franchise model in March 2025, with three franchisees already secured, presents a new channel for brand scaling and geographic expansion.
• The company maintains a professional team of certified TCM practitioners and skilled technicians, ensuring high-quality service delivery.
• A comprehensive one-stop health and wellness service offering caters to diverse customer needs across various life stages, including specialized women's health, prenatal, postpartum, and male hair care services.
• Rigorous quality assurance measures are in place for products and services, including sourcing from GMP and ISO 9001 certified suppliers, contributing to customer trust.
• Integration of TCM principles with modern technology, such as needle-free thread embedding and TCM E-plus eye care therapy, enhances service efficacy and innovation.
• The management team possesses extensive experience and expertise in the TCM-inspired wellness and beauty industry.
• A customer-centric approach with customized services aims to foster long-term relationships and customer loyalty.
• The company holds an exclusive patent license for its 'BTS (Beauty, Tailor-made, Slim) pelvic detox therapy' until July 2031.
• Investments in certificates of deposit (US$1,441,099) and US Treasury Bills (US$503,453) as of March 31, 2025, provide additional liquidity.
• Management believes the company can continue as a going concern for the next 12 months through operations and financial support from the controlling shareholder, financial institutions, and investors.

Negatives

• The auditor expressed substantial doubt about the company's ability to continue as a going concern due to working capital deficits as of March 31, 2025 and 2024.
• Cash and cash equivalents decreased from US$2,103,655 in FY2024 to US$816,771 in FY2025.
• The number of customers for beauty, wellness, and postpartum services decreased by 5.2% in FY2025, despite an increase in average customer spending.
• Revenue from consultancy services dropped to nil in FY2025 from US$112,569 in FY2024, indicating a loss of a revenue stream.
• The TCM-inspired wellness and beauty industry in Hong Kong is highly competitive, posing challenges for market share and pricing.
• Building customer trust and boosting acceptance for TCM-inspired therapies is challenging due to limited evidence-based validation and longer visible results compared to modern cosmetic treatments.
• The newly launched franchise model is unproven and may not achieve commercial success or contribute meaningfully to financial performance.
• The company relies on franchisees to uphold brand reputation and service quality, over whom it has limited day-to-day operational control.
• The relative lack of stringent laws and regulations in Hong Kong's wellness and beauty services sector poses a risk of inconsistent service quality across the industry.
• The company does not carry product liability insurance or business interruption insurance, exposing it to significant financial risks from claims or disruptions.
• The company's CEO, Kit Wong, holds management positions and directorships in other companies, potentially causing conflicts of interest and diverting her time.
• The company's Class A Ordinary Shares may be prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect its auditor for two consecutive years, despite the auditor being US-based and recently inspected.
• There is a risk of being deemed a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could result in adverse tax consequences for U.S. holders.
• The company has broad discretion in the use of net proceeds from the IPO, which may not be used effectively.
• The company's Class A Ordinary Shares may be thinly traded post-IPO, making it difficult for investors to sell at desired prices or at all.

Risks

• All operations are conducted by wholly-owned Operating Subsidiaries in Hong Kong, but due to long-arm application of PRC laws and regulations, the PRC government may exercise significant direct oversight and discretion, potentially resulting in a material change in operations and/or value of Class A Ordinary Shares.
• Uncertainties exist regarding whether the company will be required to obtain approvals from PRC authorities to list on U.S. exchanges and offer securities in the future, and failure to obtain such approvals could hinder operations and devalue shares.
• If the PRC government extends oversight and control over overseas offerings and foreign investment to Hong Kong-based issuers, it may significantly limit or completely hinder the company's ability to offer securities and cause the value of Class A Ordinary Shares to decline or become worthless.
• The enactment of the Hong Kong National Security Law could impact Hong Kong subsidiaries, which represent substantially all of the business, potentially affecting business operations, financial position, and results.
• The enforcement of laws and rules in China and Hong Kong can change quickly with little advance notice, leading to uncertainties in the legal system that could limit legal protections and materially change operations or security value.
• Political risks associated with conducting business in Hong Kong, including adverse economic, social, and/or political conditions, material social unrest, or natural disasters, could adversely affect operations.
• The company operates in a dynamic industry with a limited operating history, meaning historical results may not be indicative of future performance and profitability may not be sustained.
• Failure to compete effectively in the intense TCM-inspired wellness and beauty industry could adversely affect market share, revenues, and growth prospects.
• Business depends on the quality of service and products and ability to meet customer expectations; failure to consistently deliver desired results could harm reputation and customer loyalty.
• Significant risks are associated with contracting with third-party suppliers, including potential contaminations, defects, or non-compliance with regulations, leading to product liability and penalties.
• The relative lack of stringent laws and regulations in Hong Kong's wellness and beauty services sector poses a risk of inconsistent service quality, and any failure to maintain high standards could adversely affect reputation and performance.
• The company may become a party to litigation, legal disputes, claims, or administrative proceedings that could materially and adversely affect it through costs, diversion of resources, and reputational damage.
• The continued and collaborative efforts of senior management and key employees (TCM practitioners, technicians, support staff) are crucial; loss of their services or failure to attract/retain talent could harm the business.
• Failure to obtain and maintain requisite licenses, permits, registrations, and filings, or to obtain additional ones due to new regulations or business expansion, could materially and adversely affect operations.
• Inability to protect intellectual property (trademarks, trade secrets, patents) could diminish brand value and adversely affect the business, including misuse by franchisees.
• An economic downturn may adversely affect consumer discretionary spending and demand for the company's products and services.
• Business expansion into other countries requires substantial investment and resources and is subject to risks and uncertainties, with no guarantee of success.
• The business is subject to complex and evolving product safety laws, regulations, and standards; non-compliance or product defects could lead to recalls, penalties, and product liability claims.
• Failure to appropriately respond to changing consumer preferences and demand for new products could significantly harm customer relationships and product sales.
• If products do not have intended effects or cause undesirable side effects, the business, financial condition, results of operations, and prospects could be harmed significantly.
• Inherent risks relating to product liability and personal injury claims exist, and the company does not carry product liability insurance.
• The auditor has expressed substantial doubt about the company's ability to continue as a going concern based on working capital deficits.
• The CEO, Kit Wong, holds other management positions and directorships, potentially causing conflicts of interest and impacting her time devoted to the company.
• The recently launched franchise model is unproven and may not succeed.
• Reliance on dividends and other distributions from Hong Kong subsidiaries to fund cash and financing requirements, with potential future restrictions by the PRC government on cash transfers out of Hong Kong.
• The laws of BVI provide limited protections for minority shareholders compared to the U.S., potentially limiting recourse for dissatisfied shareholders.
• Difficulties may arise in effecting service of legal process, enforcing foreign judgments, or bringing actions in Hong Kong against the company or its management based on Hong Kong laws.
• The company's Class A Ordinary Shares may experience extreme stock price volatility unrelated to operating performance, making it difficult for investors to assess value and potentially resulting in substantial losses.
• The Class A Ordinary Shares may be thinly traded, making it difficult to sell shares at or near ask prices or at all.
• Failure to satisfy or continue to satisfy Nasdaq Capital Market listing requirements could lead to delisting, negatively impacting share price and liquidity.
• Sales or availability for sale of substantial amounts of Class A Ordinary Shares in the public market could adversely affect the market price.
• Investors will experience immediate and substantial dilution in the net tangible book value of Class A Ordinary Shares purchased.
• Dividends are at the discretion of the Board of Directors, so investors must rely on price appreciation for return on investment.
• As an emerging growth company, the company is subject to lessened disclosure requirements, which may make Class A Ordinary Shares less attractive to investors.
• The company will incur increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• As a foreign private issuer, the company may file less or different information with the SEC and follow home-country corporate governance practices, potentially affording less protection to shareholders.
• There is no assurance that the company will not be deemed a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. holders.
• Nasdaq may apply additional and more stringent criteria for initial and continued listings due to the relatively small size of the offering and large insider holdings.
• The company may be subject to material litigation, investigations, and enforcement actions by regulators and governmental authorities.

Future Outlook

The company plans to expand its international market share by entering new geographic regions, particularly Southeast Asia, through thorough market research and potential franchise opportunities. It intends to build strategic partnerships for market promotion, product development, and sales activities, including collaborations with cosmetic brands, health institutions, retailers, and research institutions. Significant investment is planned for technological innovation and R&D to develop new beauty products and services, focusing on ingredient research for skincare and adopting advanced beauty instruments. The company also aims to establish a strong brand image through differentiation, marketing campaigns, quality assurance, and enhanced customer experience, including hosting beauty seminars. Furthermore, it plans to diversify its product and service offerings, specifically expanding TCM-inspired wellness solutions tailored for male consumers to address concerns like insomnia, chronic fatigue, acne, and male pattern baldness.

Management Comments

• "We believe that our TCM-inspired services can help balance the female endocrine system and improve womens constitution and overall health."
• "We believe that diversifying our TCM-based offerings for male consumers will strengthen our competitive position and support our long-term revenue growth."
• "We are confident that we can improve customer satisfaction and loyalty by providing high-quality customer service and personalized experiences."
• "We believe our ability to continue as a going concern is not contingent upon obtaining funding from sales of our stock securities in this Offering."

Industry Context

The TCM wellness and beauty market in Hong Kong is experiencing rapid growth, with the traditional Chinese medicine service market expanding from 32.5 billion HKD in 2019 to 36.9 billion HKD in 2023 (3.2% CAGR), projected to reach 57.3 billion HKD by 2030 (6.5% CAGR). This growth is driven by increasing consumer demand for natural, holistic wellness solutions, particularly for women's health, fertility, and aesthetic needs. Government support for TCM integration into tourism and wellness, widespread gynecological symptoms, and a consumer preference for natural health and balance are key drivers in the TCM women's health market. Delayed childbearing trends and a rising focus on health and well-being are fueling the fertility-related TCM services market. The TCM beauty market is boosted by social media influence, celebrity endorsements, and increased awareness of women's health, alongside a preference for natural ingredients and gradual standardization of professional qualifications. The market is highly competitive, with both public hospitals offering standardized, lower-cost services and private institutions providing flexible, personalized, higher-cost options. Future trends indicate a shift towards one-stop health service solutions, increased customization, and a growing demand for postpartum recovery and natural beauty practices.

Comparison to Industry Standards

• The company's suppliers are required to hold Good Manufacturing Practice (GMP) certificates and comply with ISO 9001 quality management standards, aligning with recognized industry quality benchmarks.
• The company's TCM practitioners hold Registered Chinese Medicine Practitioner Certificates issued by the Hong Kong Chinese Medicine Council, adhering to statutory professional qualifications under the Chinese Medicine Ordinance.
• Technicians performing Indonesian traditional abdominal binding therapy have completed specialized training, indicating adherence to specific service delivery standards within that niche.
• The company's Japanese facial bone adjustment services are performed by TCM practitioners who are members of the Hong Kong Chinese Orthopedics Society, suggesting a commitment to specialized professional standards.
• The company's internal quality control measures, including training service providers and collecting customer feedback, are consistent with industry best practices for maintaining service quality and customer satisfaction.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.
• May from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business, with outcomes being hard to predict.

Related Party Transactions

• Ms. Kit Wong, the Controlling Shareholder, CEO, and Director, had an amount due from her of US$885,056 as of March 31, 2024, which was fully settled or collected during FY2025. As of March 31, 2025, an amount of US$214,603 was due to Ms. Wong for payments made on behalf of the company for inventories, consumables, and listing expenses.
• Ms. Wong Ting Ting (sister of Ms. Wong) received US$49,783 in staff costs, commission, and employee benefits in FY2025 (US$30,674 in FY2024).
• Ms. Liu Qiong (mother of Ms. Wong) received US$22,550 in staff costs, commission, and employee benefits in FY2025 (US$16,116 in FY2024).
• Remuneration to senior management (including Ms. Wong) totaled US$189,567 in FY2025 (US$173,034 in FY2024).
• Water F (Worldwide Hong Kong) Company Limited, owned by Ms. Wong, paid US$233,800 in employee salaries on behalf of the company in FY2025 (nil in FY2024).

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the IPO. The controlling shareholder, Ms. Kit Wong, will retain significant voting power (91.65% post-IPO), potentially limiting the influence of minority shareholders. Risks related to BVI law's limited minority shareholder protections and potential delisting under the HFCAA could impact investment value.
• Customers: Benefit from a comprehensive range of TCM-inspired beauty and wellness services, high-quality assurance, and potential expansion of service offerings and geographic reach through new wellness centers and franchisees. Increased average customer spending indicates strong customer satisfaction.
• Employees: Continued employment and potential for growth as the company expands. The company emphasizes professional training for TCM practitioners and technicians.
• Suppliers: Continued business relationships, particularly with GMP and ISO 9001 certified manufacturers for products and equipment.
• Creditors: The auditor's going concern opinion due to working capital deficits indicates a potential risk, though management has plans for financial support and improved operational efficiency.

Next Steps

• Complete the Initial Public Offering and list Class A Ordinary Shares on the Nasdaq Capital Market.
• Expand business and geographic coverage, particularly in Southeast Asia, potentially through new wellness centers and franchise opportunities.
• Pursue potential strategic investments and acquisitions to enhance market position.
• Invest in research and development for technology and product innovation, including ingredient research for skincare and adoption of advanced beauty instruments.
• Diversify product and service offerings, specifically expanding TCM-inspired wellness solutions tailored for male consumers.
• Continue to build a strong brand image through marketing campaigns, quality assurance, and enhanced customer experience, including hosting beauty seminars and workshops.
• Monitor and comply with evolving regulatory and compliance requirements in current and new markets.

Key Dates

Recommendation

Charming Medical Limited presents a compelling growth story with strong revenue and net income increases, an improving working capital position, and a clear strategy for expansion into new markets and product diversification, including a promising new franchise model. The company's focus on TCM-inspired wellness, a growing market in Hong Kong, and its commitment to quality and customer service are positive indicators. However, significant risks temper this optimism. The auditor's going concern opinion, while addressed by management's plans for financial support and operational efficiency, remains a material concern. Furthermore, the inherent uncertainties of operating in Hong Kong under potential PRC regulatory influence, the unproven nature of the new franchise model, and the lack of product liability or business interruption insurance introduce considerable risk. The dual-class share structure also means that the controlling shareholder will retain substantial voting power post-IPO, limiting minority investor influence. Given the balance of strong growth potential against substantial operational, regulatory, and financial risks, a 'hold' recommendation is appropriate for seasoned investors, suggesting observation of how the company navigates these challenges post-IPO.

Keywords

TCM-inspired wellness, Beauty Lab Group, Hong Kong, SEC filing, IPO, Nasdaq Capital Market, Traditional Chinese Medicine, Wellness services, Beauty products, Franchise model, Women's health, Postpartum care, Scalp and hair care, Financial performance, Risk factors, Corporate governance, Emerging growth company, Foreign private issuer, Kit Wong, Going concern, Regulatory risk, Data privacy, HFCAA, PFIC